Table 1.
Serum lipids in 27 patients with advanced chronic hepatitis C infection before and at the end (week 12) of direct-acting antiviral therapy
| Characteristics | HCV genotype 1, n = 15 | HCV genotype 3, n = 12 | ||||
|---|---|---|---|---|---|---|
| Baseline | Week 12 | p value* | Baseline | Week 12 | p value* | |
| Sex, n (M/F) | 11/4 | – | 7/5 | – | ||
| Age (yr), median (range) | 62 | (48–74) | – | 56 | (36–65) | – |
| HCV RNA log10 (IU/ml), mean ± SD | 5.80 ± 0.82 | 0 | – | 5.33 ± 0.74 | 0 | – |
| Total cholesterol (mmol/l), median (IQR) | 4.25 (1.75) | 4.30 (1.15) | 0.662† | 4.10 (1.18) | 4.40 (1.90) | 0.652† |
| LDL-C (mmol/l), mean ± SD | 2.27 ± 0.83 | 2.10 (0.74) | 0.666‡ | 2.37 ± 0.84 | 2.48 ± 0.76 | 0.762† |
| Apolipoprotein B (g/l), median (IQR) | 0.79 (0.49) | 0.76 (0.24) | 0.512† | 0.87 (0.47) | 0.86 (0.42) | 0.722† |
| HDL-C (mmol/l), mean ± SD | 1.44 ± 0.48 | 1.56 ± 0.46 | 0.511‡ | 1.26 ± 0.40 | 1.36 ± 0.44 | 0.603‡ |
| Apoprotein A1 (g/l), mean ± SD | 1.63 ± 0.29 | 1.63 ± 0.43 | 0.972‡ | 1.38 ± 0.30 | 1.50 ± 0.39 | 0.432‡ |
| Triglyceride (mmol/l), median (IQR) | 1.20 (1.40) | 1.10 (0.90) | 0.456† | 1.25 (0.55) | 1.50 (0.90) | 0.773† |
| ApoB/apoA1 ratio, median (IQR) | 0.46 (0.39) | 0.46 (0.35) | 0.593† | 0.62 (0.24) | 0.51 (0.25) | 0.657† |
| TG/HDL-C ratio, median (IQR) | 0.92 (1.01) | 0.69 (0.89) | 0.505† | 1.08 (0.99) | 1.00 (0.82) | 0.653† |
| TC/HDL-C ratio, median (IQR) | 2.71 (2.70) | 2.63 (1.92) | 0.437† | 3.23 (1.66) | 3.39 (1.63) | 0.838† |
| Anti-apoA1 antibodiesa, median (IQR) | 34.20 (27.70) | 37.30 (27.23) | 0.565† | 45.60 (32.40) | 37.00 (32.43) | 0.510† |
ApoB/apoA1, apolipoprotein B/apolipoprotein A1 ratio
Parametric variables shown as the mean plus/minus standard deviation. Non-parametric variables shown as the median and the interquartile range
IQR interquartile range, SD standard deviation; TC/HDL-C total cholesterol/high-density lipoprotein cholesterol, TG/HDL-C triglyceride/high-density lipoprotein cholesterol
*p values presented are for the comparison between variables at baseline and week 12. p < 0.05 was considered significant
†p value calculated using the non-parametric Kruskal-Wallis test
‡p value calculated using the parametric t test
aThe anti-ApoA-1 antibody positivity cutoff was predefined at 37%, which corresponded to an OD405 nm of 0.6 as previously validated and described (18–20)